Biotechnology · La Jolla, California, United States
$1.76
-2.23% (-$0.04)2026-07-09
Net Income-$2.0M
EPS$-1.61
Market Cap$2.8M
Price Performance
Historical data including institutional events
Company Profile
W
W. Hertz
CEO & Executive Director
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The companyâs portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
- Founded
- 2018
- Employees
- 4
- Headquarters
- La Jolla, California, United States
- Website
- www.gribio.com
Peer ComparisonRevenue ($B)
▾Loading company sections...